Primary Site >> Liver Cancer

Gene >> SSTR2

  • 2000
  • 2002
  • 2004
  • 2005
  • 2007
  • 2009
  • 2012
  • 2013
  • 2014
  • 2015
  • 2017
Ref: Treatment of hepatocellular cancer with the long acting somatostatin analog lanreotide in vitro and in vivo.
PMID: 10811995
Ref: Molecular cytogenetic evaluation of virus-associated and non-viral hepatocellular carcinoma: analysis of 26 carcinomas and 12 concurrent dysplasias.
PMID: 11004697
Ref: In- and Y-DOTA-lanreotide: results and implications of the MAURITIUS trial.
PMID: 11965610
Ref: Differential expression of somatostatin receptor subtypes in hepatocellular carcinomas.
PMID: 15246216
Ref: Octreotide inhibits proliferation and induces apoptosis of hepatocellular carcinoma cells.
PMID: 15456543
Ref: Somatostatin receptor subtype 2-mediated scintigraphy and localization using (99m)Tc-HYNIC-Tyr(3)-octreotide in human hepatocellular carcinoma-bearing nude mice.
PMID: 15991301
Ref: [The study of inhibition effect of octreotide on the growth of hepatocellular carcinoma xenografts in situ in nude mice].
PMID: 16008961
Ref: [Correlation of somatostatin receptor expression in human hepatocellular carcinoma tissue to serum alpha-fetoprotein concentration].
PMID: 17626741
Ref: Mechanisms and influence of octreotide-induced regulation of somatostatin receptor 2 on hepatocellular carcinoma.
PMID: 19590186
Ref: [Effects of octreotide on necrosis of hepatocellular carcinoma xenografts in nude mice].
PMID: 19624890
Ref: [Induction of necrosis in the hepatocellular carcinoma HepG2 xenografts treated with SOM230].
PMID: 19874692
Ref: Lanreotide treatment of metastatic hepatocellular carcinoma resulting in partial regression and more than 3 years of progression-free survival.
PMID: 22870795
Ref: Somatostatin receptor subtypes 2 and 5 are associated with better survival in operable hepatitis B-related hepatocellular carcinoma following octreotide long-acting release treatment.
PMID: 24137418
Ref: Hepatic somatostatin receptor 2 expression during premalignant stages of hepatocellular carcinoma.
PMID: 24163059
Ref: SUV of [68Ga]DOTATOC-PET/CT Predicts Response Probability of PRRT in Neuroendocrine Tumors.
PMID: 25319765
Ref: Somatostatin receptors in resected hepatocellular carcinoma: status and correlation with markers of poor prognosis.
PMID: 27391928
Ref: [Differences of Therapeutic Efficacy Between Different Kinds of Somatostatin Analogue for Primary Hepatocellular Carcinoma].
PMID: 28752973
Ref: Somatostatin and CXCR4 chemokine receptor expression in hepatocellular and cholangiocellular carcinomas: tumor capillaries as promising targets.
PMID: 29282035